Scientists create non-digestible aptamer
German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2201 entries already.
Entries by Thomas Gabrielczyk
SynaptixBio Ltd gets FDA ODD for leukodystrophy
Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
Pierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc.
Swiss vaccine developer Limma Tech get CARB-X grant
Swiss multivalent vaccine developer LimmaTech Biologics AG has been awarded US$2.2m rom the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
Curve Therapeutics raises £40.5m in Series A financing
Intracellular cancer target screening specialist Curve Therapeutics Ltd has closed a £40.5m financing led by Pfizer Ventures to advance its preclinical pipeline of small cyclic petides.
Pacifico Biolabs raises US$3.3m in pre-seed round
German foodtech start-up Pacifico Biolabs has raised US$3.3m to push the development of healthy animal-free, carbon-neutrally produced fish and seafood.
Gene therapy supplier MIP Discovery closes £7M Series A financing
MIP Discovery Ltd has closed a £7M Series A financing to drive commercialisation of its synthetic affinity reagents in cell and gene therapy.
Vidac Pharma Holding plc reports preclinical proof of principle
London-based Vidac Pharma Holding plc reported that its Warburg effect blocker VDA-1275 increased efficacy of chemotherapeutics 1000-fold in human organoid cancer models for liver cancer.
GMP PharmaCongress 2024 – Vaccines, ATMP and more
In addition to classic aseptic manufacturing topics, the international GMP PharmaCongress and GMP Pharmatechnica Expo 2024 in Wiesbaden will also address global challenges with modern vaccines and novel drugs based on cell and gene therapies. The event thus offers a comprehensive programme for experts from pharmaceutical manufacturing, technology and quality assurance from industry, labs and authorities, as well as a platform for the direct exchange of knowledge and experience.
Roche leads Freenome Inc US$257m financing
Multi-omics liquid biospy specialist Freenome Inc. has baged US$254m in a financing round led by Roche AG to fund early cancer detection in 6,200 patients using its AI-guided cancer detection platform.